https://www.gosh.nhs.uk/news/new-commercial-agreement-for-gene-therapy-at-gosh/
New commercial agreement for gene therapy at GOSH
16 Mar 2023, 9:57 a.m.
Great Ormond Street Hospital for Children (GOSH) and Leucid Bio have entered a new commercial agreement to manufacture a gene therapy product.
Gene and cell therapies are the cutting-edge in clinical research for cancer treatments. They hold promise to offer personalised cancer treatments, including for rare forms that sadly affect children and young people. This year, GOSH opened new facilities for manufacturing gene and cell therapies. These facilities have increased our capacity to support development of cell and gene therapies from the very start in discovery research to clinical trials where therapies are tested in patients.
A new agreement with GOSH and Leucid Bio
In a new agreement, GOSH will work with Leucid Bio, a biotechnology company, at the state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children and provide quality assurance services required for manufacture of their gene therapy product, called LEU011.
LEU011 is a type of CAR T-cell therapy which reprogrammes these immune cells to recognise and destroy cancer cells. The company’s therapy has a particular structure on the cell surface that has been shown through early-stage research to work more effectively at targeting cancers than other types of CAR T-cell therapies.
Leucid Bio will submit for clinical trial approvals to trial LEU011, a type of gene therapy product over the next few months. In this first trial for patients, they hope to show that LEU011 improves outcomes and can save the lives of patients with solid tumours and blood cancers.
At Great Ormond Street Hospital, we see children with the most rare and complex cancers. There have been incredible strides forward in the treatment that we can offer, however, sadly for many these still don’t work. Gene therapies offer hope for better, and potentially curative treatments which is why we’re excited to support innovation in gene therapies through access to these highly specialist and unique facilities.“
We are extremely pleased to enter this first of its kind collaboration with GOSH to manufacture our lead asset, LEU011, for use in human studies. Additionally, we are pleased to have started a process with GOSH to examine the feasibility of applying our approach in the paediatric setting where there remains a great unmet need for new therapies.”
More information about CAR T-cell therapy
Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.
Genes may help to predict which children will respond well to arthritis treatment
A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.
Making it easier to invest in frontline care
GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.
Patients and public help create multilingual resources for expectant parents
A group of clinicians and researchers at GOSH have developed information about a test offered in pregnancy called prenatal sequencing in the UK’s 12 most common languages.